MX2017001971A - Composiciones antimetanogenicas y sus usos. - Google Patents

Composiciones antimetanogenicas y sus usos.

Info

Publication number
MX2017001971A
MX2017001971A MX2017001971A MX2017001971A MX2017001971A MX 2017001971 A MX2017001971 A MX 2017001971A MX 2017001971 A MX2017001971 A MX 2017001971A MX 2017001971 A MX2017001971 A MX 2017001971A MX 2017001971 A MX2017001971 A MX 2017001971A
Authority
MX
Mexico
Prior art keywords
compositions
methanogenic
antimethanogenic statin
release
methanogen
Prior art date
Application number
MX2017001971A
Other languages
English (en)
Inventor
Mathur Ruchi
Pimentel Mark
Kanzer Steve
WACHER Vince
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2017001971A publication Critical patent/MX2017001971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención hace referencia, en parte, a métodos y composiciones para el tratamiento de trastornos asociados con metanógenos como, por ejemplo, síndrome de intestino irritable (SII). En particular, se brindan formulaciones con liberación modificada que comprenden al menos una estatina antimetanogénica que liberan la estatina antimetanogénica en los intestinos.
MX2017001971A 2014-08-13 2015-08-13 Composiciones antimetanogenicas y sus usos. MX2017001971A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US201462043789P 2014-08-29 2014-08-29
US201462043649P 2014-08-29 2014-08-29
US201562141355P 2015-04-01 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2017001971A true MX2017001971A (es) 2017-09-15

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001971A MX2017001971A (es) 2014-08-13 2015-08-13 Composiciones antimetanogenicas y sus usos.

Country Status (12)

Country Link
US (5) US9956292B2 (es)
EP (1) EP3179983A4 (es)
JP (1) JP6667526B2 (es)
KR (1) KR102425303B1 (es)
CN (1) CN106687107B (es)
AU (1) AU2015301596B2 (es)
BR (1) BR112017002761A2 (es)
CA (1) CA2955666A1 (es)
IL (1) IL250568B (es)
MX (1) MX2017001971A (es)
RU (1) RU2697851C2 (es)
WO (1) WO2016025762A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226505B2 (en) 2013-03-15 2019-03-12 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10328151B2 (en) 2014-08-13 2019-06-25 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10519515B2 (en) 2013-03-15 2019-12-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
US20190277833A1 (en) * 2016-05-19 2019-09-12 Synthetic Biologics, Inc. Anti-methanogenic compositions
US20200390742A1 (en) * 2016-06-21 2020-12-17 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
MX2019006821A (es) 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
WO2018112215A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3554342A1 (en) * 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN111511353A (zh) * 2017-06-21 2020-08-07 田边三菱制药株式会社 耐胃液的控释口服剂型
MX2022003883A (es) * 2019-10-09 2022-07-19 Scherer Technologies Llc R P Formulaciones en capsulas de gel blando de origen no animal, metodos de preparacion y metodos de uso de las mismas.
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals
CA3235479A1 (en) * 2021-10-19 2023-04-27 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
ES2218530T3 (es) 1993-10-19 2004-11-16 Commonwealth Scientific And Industrial Research Organisation Uso de una preparacion inmunogenica para mejorar la utilizacion de elementos nutritivos por los animales rumiantes o similares a los rumiantes.
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
CA2220451A1 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
CA2389616A1 (en) 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd. Liver selective therapy
AU768950B2 (en) 1999-11-08 2004-01-08 Andrx Corporation HMG-COA reductase inhibitor extended release formulation
ES2272493T3 (es) 2000-06-13 2007-05-01 Unilever N.V. Producto alimenticio que contiene lactobacilos no viables.
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
US7098239B2 (en) * 2001-06-20 2006-08-29 Merck & Co., Inc Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2771788C (en) 2002-05-20 2022-03-22 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
ES2373175T3 (es) 2002-07-18 2012-02-01 Agricultural Research Council Cepa de megasphaera elsdenii y sus usos.
JP2006503023A (ja) 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
US20070280949A1 (en) 2003-07-10 2007-12-06 Michelle Alfa Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
WO2005058861A1 (en) 2003-12-16 2005-06-30 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2005115380A2 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis INTESTINAL MICROBIOMA AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR OBESITY-RELATED DISORDER
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
US7879802B2 (en) * 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
JP6297769B2 (ja) 2009-02-02 2018-03-20 クロモセル コーポレーション 新規の細胞株および方法
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CN103142552A (zh) 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
BR112015022825A2 (pt) 2013-03-15 2017-11-07 Cedars Sinai Medicalcenter métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2955666A1 (en) 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
EP3277274A4 (en) 2015-04-01 2018-12-05 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20200390742A1 (en) 2016-06-21 2020-12-17 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226505B2 (en) 2013-03-15 2019-03-12 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10519515B2 (en) 2013-03-15 2019-12-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10688149B2 (en) 2013-03-15 2020-06-23 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10328151B2 (en) 2014-08-13 2019-06-25 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10668159B2 (en) 2014-08-13 2020-06-02 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US11344501B2 (en) 2014-08-13 2022-05-31 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Also Published As

Publication number Publication date
KR20170041769A (ko) 2017-04-17
IL250568B (en) 2021-05-31
US20230036151A1 (en) 2023-02-02
US20200323781A1 (en) 2020-10-15
US9956292B2 (en) 2018-05-01
CA2955666A1 (en) 2016-02-18
US10668159B2 (en) 2020-06-02
JP2017528516A (ja) 2017-09-28
RU2017106896A (ru) 2018-09-13
CN106687107B (zh) 2020-12-25
EP3179983A4 (en) 2018-01-10
AU2015301596B2 (en) 2020-04-16
AU2015301596A1 (en) 2017-02-02
US20160045604A1 (en) 2016-02-18
RU2017106896A3 (es) 2019-03-19
KR102425303B1 (ko) 2022-07-25
CN106687107A (zh) 2017-05-17
RU2697851C2 (ru) 2019-08-21
US20190328885A1 (en) 2019-10-31
JP6667526B2 (ja) 2020-03-18
US20180289816A1 (en) 2018-10-11
IL250568A0 (en) 2017-03-30
WO2016025762A1 (en) 2016-02-18
US10328151B2 (en) 2019-06-25
US11344501B2 (en) 2022-05-31
BR112017002761A2 (pt) 2017-12-19
EP3179983A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017006217A (es) Polinucleotidos moduladores.
MX2018000511A (es) Derivados de fenoximetilo.
GB2541571A (en) Pharmaceutical compositions
TW201613901A (en) New compounds
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017501864A1 (en) Compositions and methods for treating autism
IN2014CH00840A (es)
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2016009073A (es) Acido (s)-3'-metil-abscisico y esteres del mismo.

Legal Events

Date Code Title Description
FG Grant or registration